4.7 Article

Addressing Missing Data in Clinical Trials

Journal

ANNALS OF INTERNAL MEDICINE
Volume 154, Issue 2, Pages 113-+

Publisher

AMER COLL PHYSICIANS
DOI: 10.7326/0003-4819-154-2-201101180-00010

Keywords

-

Funding

  1. National Institutes of Health/National Institute of Allergy and Infectious Disease [R37 AI 29168]

Ask authors/readers for more resources

The reliability and interpretability of results from clinical trials can be substantially reduced by missing data. Frequently used approaches to address these concerns, such as upward adjustments in sample sizes or simplistic methods for handling missing data, including last-observation-carried-forward, complete-case, or worst-case analyses, are usually inadequate. Although rational imputation methods may be useful to treat missingness after it has occurred, these methods depend on untestable assumptions. Thus, the preferred and often only satisfactory approach to addressing missing data is to prevent it. Procedures should be in place to maximize the likelihood that outcome data will be obtained at scheduled times of evaluation for all surviving patients who have not withdrawn consent. To meaningfully reduce missing data, it is important to recognize and address many factors that commonly lead to higher levels of missingness. Ann Intern Med. 2011;154:113-117.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available